NASDAQ · Biotechnology · USD
Bright Minds Biosciences Inc. (DRUG) Stock Analysis
Bright Minds Biosciences Inc. (DRUG) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
DRUG Key Statistics
As of Oct 21, 2026Trading
- Open
- $55.34
- Previous Close
- $55.20
- Day's Range
- 49.80–59.71
- 52-Week Range
- 47.23–123.75
- Volume
- 156.35K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.23
Valuation
- Market Cap
- $497.54M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −2.05
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$12.23M
- Shares Outstanding
- 9.86M
- 1-Year Return
- −27.35%
Dividend and dates
- Avg Volume
- 143.45K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, DRUG closed at $50.44, −27.35% over 1 year.
Bright Minds Biosciences Inc. (DRUG) has a market capitalization of $497.54M.
In fiscal 2025, DRUG reported revenue of $0.00.
DRUG Stock Return by Calendar Year
Bright Minds Biosciences Inc. (DRUG) return since Mar 2021: what $10,000 became
- 1 year
- $10,000 $7,265
- −27.35%
- 5 years
- $10,000 $14,875
- +48.75%
- Since Mar 2021
- $10,000 $18,681
- +86.81%
If you had invested $10,000 in Bright Minds Biosciences Inc. (DRUG) at the close on March 22, 2021, the earliest close on record here, it would have been worth $18,681 at the close on October 21, 2026: +86.81% in total, +11.85% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −35.37% |
| 2025 | +116.66% |
| 2024 | +2,418.88% |
| 2023 | −61.35% |
| 2022 | −76.66% |
| 2021 (partial year) | −41.30% |
As of October 21, 2026.
DRUG Revenue and Earnings by Fiscal Year
FY ends September| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$12.23M | — |
| 2024 | $0.00 | −$2.80M | — |
| 2023 | $0.00 | −$7.37M | — |
| 2022 | $0.00 | −$14.96M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$13.94M | −$12.23M | — |
| 2024 | $0.00 | — | −$2.82M | −$2.80M | — |
| 2023 | $0.00 | — | −$7.39M | −$7.37M | — |
| 2022 | $0.00 | — | −$14.98M | −$14.96M | — |
Annual figures as reported, in the company's reporting currency. As of September 30, 2025.
Recent News
Wolfe Research Initiates Coverage On Bright Minds Biosciences with Outperform Rating, Announces Price Target of $150
BenzingaBright Minds Biosciences And 2 More Canadian Biotech Stocks
YahooBright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
YahooBright Minds Biosciences to Present at Upcoming Conferences
YahooHC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target
BenzingaBTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target
Benzinga
All 8 articles ↓Show fewer ↑
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B